

Report of the Independent Auditors pursuant to art. 14 of Legislative Decree no. 27 January 2010, n. 39

To the sole shareholder of
Ranbaxy Italy SpA

Report on financial statements ended 31 March 2016

We conducted the audit of the enclosed financial statements of Ranbaxy Italy SpA ended on March 31, 2016, represented by the balance sheet at 31 March 2016, the income statement for the fiscal year closed at that date, and the notes.

Directors liability over the financial statements

Directors are responsible for the preparation of financial statements aimed at presenting a true and fair view in accordance with the regulations governing their drafting.

Independent Auditors liability

Our responsibility is to express an opinion on the financial statements based on our audit.

We have carried out our audit in accordance with International auditing standards (ISA Italia) developed according to art. 11, comma 3, of D.Lgs. 39/10. Such principles require compliance to ethical standards, as well as the planning and implementation of accounting audit in order to acquire reasonable reassurance the statements do not contain significant errors.

The accounting audit implies the implementation of procedures aimed at the acquisition of evidences to support amounts and information contained in the financial statements. Procedures chosen depend on the auditor professional opinion, including the assessment of risk of significant mistakes in the statements, due to fraud or to behaviors or unintentional events. When conducting risk assessment, the auditor takes into consideration the internal control over the financial statements preparation aimed at providing a true and fair view; this in order to define audit procedures appropriate to circumstances, and not to express opinion over the efficacy of the company internal control. The accounting audit includes also the judgment over the appropriateness of accounting principles adopted, the reasonableness of accounting estimations done by Directors, as well as the judgment on the overall financial statements presentation.

We believe we have acquired adequate elements for expressing our opinion.

Opinion

In our opinion, the financial statements of Ranbaxy Italy SpA at 31 March 2016 give a true and fair view of the financial and equity position of Ranbaxy Italy SpA and of the economic result for the fiscal year closed on that date, according to Italian regulations ruling financial statements preparation.

Other topics

The financial statements of Ranbaxy Italy S.p.A. for the year ended March 31, 2015 were audited by another auditor which, on May 25, 2015, expressed an unmodified opinion on those financial statements.

The Company, as required by law, has included in the notes to the essential data of financial statements of the company which exercises management and coordination activities. Our opinion on the financial statements of Ranbaxy Italy S.p.A. does not extend to such data.

Report on other law regulations

Opinion on the consistency of the management report with the financial statements

We have performed the procedures required in ISA (SA Italy) n. 720B in order to express, as required by law, an opinion on the consistency of the management report, which is the responsibility of the Directors of Ranbaxy Italy S.p.A., with the financial statements of Ranbaxy Italy S.p.A. at 31 March 2016. In our opinion, the management report is consistent with the financial statements of Ranbaxy Italy S.p.A. to March 31, 2016.

Milan, July 11, 2016

Crowe Horwath AS SpA

Alessandro Ruina.